US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia
Attachment Inhibitor Aimed At Heavily Pre-Treated Patients
Executive Summary
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
You may also be interested in...
Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy
A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.
FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen
ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.
Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
Need a specific report? 1000+ reports available
Buy Reports